Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

Cancer Immunology, Immunotherapy

Volumn 63, Issue 8, 2014, Pages 787-796

  Smith, David A ^a,b   Conkling, Paul ^b,c   Richards, Donald A ^b,d   Nemunaitis, John J ^e   Boyd, Thomas E ^b,f   Mita, Alain C ^g   De La Bourdonnaye, Guillaume ^h,i   Wages, David ^j,k   Bexon, Alice S ^l  

^a Vancouver Cancer Center   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c Virginia Oncology Associates   (United States)

^d TEXAS ONCOLOGY   (United States)

^e Mary Crowley Cancer Research Centers   (United States)

^f North Star Lodge Cancer Center   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h MERCK SERONO S A   (Switzerland)

ⁱ Philip Morris Research and Development   (Switzerland)

^j EMD Serono   (United States)

^k IQVIA   (United States)

^l HYBRIDON INC   (United States)

more..

Author keywords

Advanced metastatic NSCLC; IMO 2055 (EMD 1201081); Phase I; Recommended phase II dose; TLR9 agonist

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; ERLOTINIB; IMO 2055; UNCLASSIFIED DRUG;

ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CAUSE OF DEATH; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENCEPHALOMALACIA; FATIGUE; FEMALE; FEVER; HUMAN; HYPOTENSION; HYPOXIA; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC ACIDOSIS; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PALATE DISEASE; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SEPTIC SHOCK; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY; TREATMENT RESPONSE; TUMOR VOLUME; VERY ELDERLY; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 84906791645     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1547-6     Document Type: Article

References (37)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236
2. National Comprehensive Cancer Network (NCCN) (2012) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-small cell lung cancer version 3. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed 4 Sep 2013
3. Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R et al (2011) Treatment of advanced non small cell lung cancer. J Thorac Dis 3:122-133
4. Ho C, Davies AM, Lara PN Jr, Gandara DR (2006) Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin Lung Cancer 7(Suppl 4):S118-S125 (Pubitemid 44056780)
5. Taxotere [product monograph] (2013) Revised Aug 2013. Bridgewater, NJ: sanofi-aventis U.S. LC. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2010/020449s059lbl.pdf. Accessed 16 Sep 2013
6. Alimta [prescribing information] (2013) Revised May 2013. Indianapolis, IN: Eli Lilly and Company. http://pi.lilly.com/us/alimtapi.pdf. Accessed 16 Sep 2013
7. Tarceva [product information] (2013) Revised May 2013. South San Francisco, CA: Genentech, Inc. http://www.gene.com/download/pdf/tarceva- prescribing.pdf. Accessed 16 Sep 2013
8. Iressa [summary of product characteristics] (2011) Cheshire, UK: AstraZeneca UK Limited. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/001016/WC500036358.pdf. Accessed 16 Sep 2013
9. Stinchcombe TE, Socinski MA (2008) Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13(Suppl 1):28-36
10. Byers LA, Heymach JV (2007) Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 8(Suppl 2):S79-S85 (Pubitemid 46569722)
11. Reck M, Crinò L (2009) Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 63:1-9
12. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES et al (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555
13. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L et al (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25:4743-4750 (Pubitemid 350086476)
14. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA et al (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377:1846-1854
15. Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S et al (2006) Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 12:577-583 (Pubitemid 43166152)
16. Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G et al (2007) TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA 104:12468-12473 (Pubitemid 47206161)
17. Wang D, Kandimalla ER, Yu D, Karr R, Agrawal S (2008) Antitumor activity of IMO-2055, an agonist of TLR9, in combination with erlotinib and bevacizumab in non-small cell lung cancer xenografts in mice. ACR Meeting Abstracts 2008:abstr 2078
18. Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925-937
19. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
20. Avastin [prescribing information] (2011) Revised September 2011. South San Francisco, CA: Genentech, Inc. http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/125085s225lbl.pdf. Accessed 16 Sep 2013
21. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
22. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
23. Cohen E, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S et al (2009) Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 10:247-257
24. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E et al (2010) A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 66:1051-1057
25. Yau T, Wong H, Chan P, Yao TJ, Pang R, Cheung T et al (2012) Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs 30:2384-2390
26. Moore DJ, Hwang J, McGreivy J, Park S, Malik S, Martin R et al (2005) Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors. J Clin Oncol 23(16S): abstract 2503
27. Machiels JP, Kaminsky MC, Keller U, Brümmendorf TH, Goddemeier T, Forssman U et al (2013) Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 31:1207-1216
28. Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M et al (2012) A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 23:72-77
29. Malik S, Hwang J, Cotarla I, Sullivan T, Kerr R, Marshall J et al (2007) Initial phase 1 results of gemcitabine, carboplatin and IMO-2055, a toll like receptor 9 (TLR9) agonist, in patients (pts) with advanced solid tumors. J Thorac Oncol 2(8 Suppl 4):S726-S727, abstract P3-112
30. Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE et al (2011) Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 29:2667-2674
31. Sánchez-González PD, López-Hernández FJ, López-Novoa JM, Morales AI (2011) An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol 41:803-821
32. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115-124 (Pubitemid 47262919)
33. Guha M (2012) Anticancer TLR agonists on the ropes. Nat Rev Drug Discov 11:503-505
34. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ et al (2012) In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 119:355-363
35. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH et al (2010) In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 28:4324-4332
36. Stevenson FK, Johnson PW (2010) Harnessing innate immunity to suppress lymphoma. J Clin Oncol 28:4295-4296
37. Yan J, Hua F, Liu HZ, Yang HZ, Hu ZW (2012) Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice. Acta Pharmocol Sin 33:503-512